The Federal Trade Commission’s (FTC) intensified efforts to address drug pricing have brought attention to the practice of “junk” Orange Book listings. These listings, often criticized for allegedly inflating drug prices by delaying generic competition, are a key focus in the current regulatory environment.
In light of recent cases, such as the FTC’s activity in the Teva v. Amneal case, legal analysts predict that branded drug manufacturers will continue to face scrutiny from the commission. Attorneys at Ropes & Gray have highlighted this trend, anticipating ongoing regulatory actions aimed at purportedly improper listings in the FDA’s Orange Book.
This approach aligns with the broader agenda of the Biden administration to combat artificially high drug prices. For more detailed information, visit the Law360 article.